These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
308 related items for PubMed ID: 37507210
1. The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials. Denis A, Sztejkowski C, Arnaud L, Becker G, Felten R. RMD Open; 2023 Jul; 9(3):. PubMed ID: 37507210 [Abstract] [Full Text] [Related]
6. Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors. Chan J, Gladman D. Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):415-426. PubMed ID: 31171312 [Abstract] [Full Text] [Related]
7. Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs. Soriano ER, Acosta-Felquer ML, Luong P, Caplan L. Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):793-806. PubMed ID: 25488785 [Abstract] [Full Text] [Related]
8. Treatment of axial spondyloarthritis: an update. Danve A, Deodhar A. Nat Rev Rheumatol; 2022 Apr; 18(4):205-216. PubMed ID: 35273385 [Abstract] [Full Text] [Related]
9. The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: A systematic review of clinical trials. Kawka L, Chevet B, Arnaud L, Becker G, Carvajal Alegria G, Felten R. Autoimmun Rev; 2024 Apr; 23(7-8):103590. PubMed ID: 39122202 [Abstract] [Full Text] [Related]
10. Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials. Séauve M, Auréal M, Laplane S, Lega JC, Cabrera N, Coury F. Joint Bone Spine; 2024 May; 91(3):105673. PubMed ID: 38042364 [Abstract] [Full Text] [Related]
11. Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis. Braun J, Kiltz U, Baraliakos X. Expert Opin Biol Ther; 2023 Feb; 23(2):195-206. PubMed ID: 36511882 [Abstract] [Full Text] [Related]
12. New developments in ankylosing spondylitis-status in 2021. Klavdianou K, Tsiami S, Baraliakos X. Rheumatology (Oxford); 2021 Dec 24; 60(Suppl 6):vi29-vi37. PubMed ID: 34951921 [Abstract] [Full Text] [Related]
13. Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review. Gialouri CG, Pappa M, Evangelatos G, Nikiphorou E, Fragoulis GE. Autoimmun Rev; 2023 Jul 24; 22(7):103357. PubMed ID: 37150489 [Abstract] [Full Text] [Related]